ANCHOR GROWKids, Youth & Family Support
ANCHOR ↗
RESEARCH + CHANGE DESK

Read the evidence.
Not just the headline.

Autism research can be promising, political, technical, commercial and personal at the same time. GROW separates source type, certainty, current status and what—if anything—a finding changes for a family today.

Seven questions before a headline changes your plan

  1. What kind of source is this: preprint, peer-reviewed study, systematic review, guideline, FDA action, government surveillance, advocacy statement or marketing?
  2. What population was studied, and does it resemble the person you are making a decision for?
  3. Is the result an association, prediction, mechanism, causal estimate or treatment effect?
  4. How large is the effect in practical terms—not only statistically significant?
  5. Was the finding independently replicated?
  6. What harms, uncertainty, confounding and conflicts of interest were reported?
  7. Did professional guidance or an approved indication actually change?
DATED CURRENT DESK

Recent items parents are likely to encounter.

Active research

NIH Autism Data Science Initiative public research update

NIH held a public webinar on research progress and future directions for the Autism Data Science Initiative, including prevalence, etiology/causation, clinical services/treatments, community engagement, replication and validation. The initiative funds 13 projects and is designed to integrate diverse data while emphasizing independent validation.

Practical meaning: This is a research program—not a new diagnostic test or treatment recommendation. Parents can follow it for emerging findings while waiting for replicated results before changing care.

Source ↗
Regulatory clarification

FDA expanded Wellcovorin use for confirmed FOLR1 cerebral folate transport deficiency

The FDA approval is for adult and pediatric patients with confirmed FOLR1-related cerebral folate transport deficiency, a rare neurological disorder.

Practical meaning: The approval should not be read as FDA approval of leucovorin for autism generally. If a headline omits the genetic condition or implies a general autism indication, check the underlying FDA label and discuss individual questions with an appropriate clinician.

Source ↗
Research funding

NIH launched a $50 million Autism Data Science Initiative

NIH announced more than $50 million supporting 13 projects using genomic, epigenomic, metabolomic, proteomic, clinical, behavioral and service data, with independent replication/validation components.

Practical meaning: Large datasets can generate important hypotheses, but association, prediction and causation are different questions. Replication and transparent methods matter before findings become parent-facing recommendations.

Source ↗
Surveillance data

CDC reported 1 in 31 among 8-year-olds in 2022 ADDM surveillance

Across 16 ADDM surveillance sites, 32.2 per 1,000 8-year-old children met the autism case definition in 2022. Prevalence varied substantially by site.

Practical meaning: This is population surveillance, not an individual child’s probability and not a single Arkansas statewide prevalence number. Changes over time reflect multiple factors, including identification practices and access to evaluation/services, and do not by themselves identify one cause.

Source ↗
Clinical guidance

Developmental screening remains a routine pediatric pathway

AAP developmental surveillance and standardized screening guidance remains an important entry point for developmental concerns, with general developmental screening at 9, 18 and 30 months and autism-specific screening at 18 and 24 months.

Practical meaning: Screening identifies who may need a closer look. It is not the same as a diagnosis, and clear developmental support needs can be addressed while evaluation is still underway.

Source ↗
CHANGE GUIDES

Context behind the current conversation.

Parents’ Guide to Change Well established

The Autism Spectrum Is Not a Line From “Mild” to “Severe”

“Spectrum” is often pictured as one line. In practice, autistic traits and support needs vary across communication, sensory experience, repetitive/restricted patterns, learning, executive function, health, motor skills, self-care, safety and environment.

6–8 9–11 12–14 15–17 18–21
Read guide →
Parents’ Guide to Change Actively debated / practice changing

ABA: Understanding a Changing Conversation

Applied behavior analysis is a broad field, not one identical program. Parent experiences and autistic adult critiques have changed public discussion about goals, intensity, assent, masking, compliance, self-regulation and quality of life.

1–2 3–5 6–8 9–11 12–14 15–17
Read guide →
Parents’ Guide to Change Supported clinical pathway; science continuing

Genetic Testing After an Autism or Developmental Diagnosis

Genetic evaluation may identify a known condition in some children, clarify recurrence risk, or point to health surveillance needs. A negative result does not mean autism is not biological and does not rule out genetic contribution.

1–2 3–5 6–8 9–11 12–14 15–17
Read guide →
Parents’ Guide to Change Well supported; diagnostic practice evolving

Why Some Girls and Other Children Are Identified Later

Autism can be missed when a child’s interests, social strategies, language or outward behavior do not match older stereotypes. Masking, supportive environments and diagnostic bias can all affect when difficulties become visible.

6–8 9–11 12–14 15–17
Read guide →
Parents’ Guide to Change Well established surveillance; causes of trend are multifactorial

Why Parents Are Hearing “1 in 31”

CDC’s 2022 ADDM surveillance across 16 U.S. sites identified autism in 32.2 per 1,000 8-year-olds—about 1 in 31. ADDM is a surveillance network, not a national census, and site estimates vary.

Birth–11 mo 1–2 3–5 6–8 9–11 12–14 15–17
Read guide →
Parents’ Guide to Change Active research / multifactorial

Why More Children Are Being Identified With Autism

Rising identified prevalence reflects a combination of factors that can include broader recognition, changing diagnostic/administrative practices, improved awareness, access differences and possibly changes in underlying risk. Surveillance trends do not by themselves separate these contributions.

Birth–11 mo 1–2 3–5 6–8 9–11 12–14 15–17
Read guide →
Parents’ Guide to Change Actively debated terminology

“Profound Autism”: Why the Term Is Being Debated

The term “profound autism” has been proposed to highlight people with very high lifelong support needs, often involving intellectual disability and/or minimal language. Supporters argue that these needs are easily lost in broad autism discussions; critics question boundaries, heterogeneity and whether a new label improves care.

6–8 9–11 12–14 15–17 18–21
Read guide →
Parents’ Guide to Change Well established

Why the AAC Conversation Has Changed

Modern AAC guidance rejects the idea that children must prove readiness, fail speech first, or reach a certain age/IQ before communication support is considered. AAC can supplement speech, provide backup when speech becomes unreliable or serve as a primary communication mode.

1–2 3–5 6–8 9–11 12–14 15–17
Read guide →
Parents’ Guide to Change Supported but measurement still developing

Masking and Later Identification Are Changing the Autism Conversation

Research and lived experience have increased attention to camouflaging/masking, later diagnosis and people whose outward behavior hides internal effort. Masking is not a single measurable trait and should not explain every late diagnosis, but it can be clinically relevant.

9–11 12–14 15–17 18–21
Read guide →
Parents’ Guide to Change Approved for confirmed FOLR1-CFTD; autism use remains a separate evidence question

Leucovorin Headlines: What Changed in 2026—and What Did Not

In March 2026 the FDA approved expanded Wellcovorin (leucovorin calcium) use for confirmed FOLR1-related cerebral folate transport deficiency, a rare neurological condition. That is not an FDA approval for autism broadly.

1–2 3–5 6–8 9–11 12–14 15–17
Read guide →
Parents’ Guide to Change Actively researched; causation claims require caution

Pregnancy Acetaminophen Headlines: Association Is Not the Same as Causation

Studies of prenatal medication exposure can be difficult to interpret because the reason a medication was taken—fever, infection, pain, inflammation—and family/genetic factors can also relate to outcomes. Professional guidance should be checked when headlines claim causation.

Birth–11 mo 1–2 3–5 6–8 9–11 12–14 15–17
Read guide →
Parents’ Guide to Change Well established evidence against a causal vaccine-autism link

Vaccines and Autism: How to Read Claims When Public Messaging Changes

Vaccine-autism claims have been studied for decades. Large epidemiologic studies have not supported vaccines as a cause of autism. Parents may still encounter renewed political or media claims, so the site distinguishes scientific evidence from policy rhetoric and individual vaccine-safety questions.

Birth–11 mo 1–2 3–5 6–8 9–11 12–14 15–17
Read guide →
Parents’ Guide to Change Active research

NIH Autism Data Science Initiative: What Parents Should Watch For

NIH’s Autism Data Science Initiative launched with more than $50 million supporting 13 projects that integrate diverse biological, clinical, behavioral, exposure and service datasets, with explicit replication and validation components. NIH held a public progress webinar August 19, 2026.

Birth–11 mo 1–2 3–5 6–8 9–11 12–14 15–17 18–21
Read guide →
Parents’ Guide to Change Well established heterogeneity; active discovery

Autism Genetics Is Getting More Detailed, Not Simpler

Autism is genetically heterogeneous: many common variants and a smaller number of rare variants/conditions can contribute, often interacting with broader biology and development. Finding one gene in one subgroup does not create one genetic explanation for autism.

Birth–11 mo 1–2 3–5 6–8 9–11 12–14 15–17
Read guide →
Parents’ Guide to Change

Leucovorin / Wellcovorin in 2026: Read the Exact FDA Indication

In March 2026 the FDA approved Wellcovorin for confirmed FOLR1-related cerebral folate transport deficiency, a rare neurological condition that can include developmental delay and autistic features. That regulatory action is not a general FDA approval of leucovorin for autism.

6–8 9–11 12–14 15–17 18–21
Read guide →